Bayer Schering Oncology Candidate Becomes First Syndax Pipeline Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Biopharma inlicenses Bayer’s selective histone deacetylase inhibitor to develop in combination therapies.
You may also be interested in...
Pharmion and MethylGene Collaborate On Sirtuin Inhibitors To Treat Cancer
MethylGene could get up to $79 million in milestones, 21 percent in U.S. royalties.
Pharmion and MethylGene Collaborate On Sirtuin Inhibitors To Treat Cancer
MethylGene could get up to $79 million in milestones, 21 percent in U.S. royalties.
Merck’s Zolinza Approved For Rare Skin Cancer
The oncologic is first in its class for treatment of cutaneous T-cell lymphoma.